GSK: Restructuring benefits palpable - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK: Restructuring benefits palpable

Jul 29, 2002

MNC pharma major Glaxo has reported robust numbers for 2QFY03. Sales growth has been more than 20% from Rs2.5 bn to Rs 3 bn, driven mainly by focus on high growth products. The highlight of results was a sharp rise in operating margins of the company by almost 1,370 basis points. The rise in operating margins is due to combination of restructuring benefits, reduction in employee costs and focus on high margin products.

(Rs m)2QFY022QFY03%Change
Sales 2,268 2,722 20.0%
Other Income 149 95 -36.2%
Expenditure 2,089 2,133 2.1%
Operating Profit (EBDIT) 179 589 229.0%
Operating Profit Margin (%)7.9%21.6% 
Interest - - NA
Depreciation 47 47 -1.1%
Profit before Tax 281 637 126.6%
Extraordinary Income 268 (2) 
Tax 99 231 132.7%
Profit after Tax/(Loss) 450 405 -10.0%
Net profit margin (%)19.8%14.9% 
No. of Shares (eoy) (m) 74 74  
Diluted Earnings per share* 24.2 21.7  
P/E (at current price) 17.8 
(*- annualised)   

In a conscious decision, Glaxo discontinued its rural operations and hived off several tail end brands. A better product mix and a price rise in some of its key brands helped the company in recording a substantial rise in operating profits. The results indicate that the restructuring efforts of the company are yielding results. Improved resource allocations of marketing spend, tight control on expenses and synergies from integration and reduction in staff numbers due to manufacturing rationalisation, coupled with control on the field staff and back office headcount have helped improve profits. Glaxo's management had earlier indicated that the company intends to double its operating margins over a three year period. However, we believe that a substantial portion of increase in sales is on account of de-stocking exercise initiated by the company last year and hence may not be sustainable.

The second quarter results have been marginally above our expectations. We expect margins to stabilise around 17-18%. Till further clarity emerges on the sustainability of the sales growth and the exact impact of the DPCO, we maintain our FY03E EPS estimate of Rs 19.8. At the current market price of Rs 386, the stock trades at 19x FY03E earnings.

Equitymaster requests your view! Post a comment on "GSK: Restructuring benefits palpable ". Click here!

  

More Views on News

GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Dec 1, 2021 11:37 AM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - MYLAN COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS